It can inhibit tyrosine kinase receptors, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), and can be used for renal cell carcinoma (RCC) by inhibiting VEGF-mediated endothelial cell proliferation and survival [10,11,12,13,14,15,16]. This evidence concerns the gene VEGFA and renal cell carcinoma.